What Is Cagrilintide?
Last reviewed:
Cagrilintide (research code AM833) is a long-acting lipidated analogue of amylin, the 37-amino-acid pancreatic peptide co-secreted with insulin. It is classified in the literature as a dual amylin and calcitonin receptor agonist (DACRA). Cagrilintide is an investigational molecule and is not an approved medicine.
How is Cagrilintide classified and what is its structure?
Cagrilintide is a synthetic amylin analogue carrying amino-acid substitutions that improve solubility and stability, plus a lipidation that extends its circulating half-life through albumin binding. Its development as a long-acting analogue was described by Kruse and colleagues in Journal of Medicinal Chemistry in 2021.
How is Cagrilintide’s mechanism studied in research?
Amylin acts at receptor complexes formed by the calcitonin receptor together with receptor-activity-modifying proteins (RAMPs) — the AMY receptors. Pharmacology reviews describe how these complexes are assembled and measured, and cagrilintide is characterised as engaging both amylin and calcitonin receptors, hence the DACRA label.
Mode-of-action studies use radioligand binding, cAMP signalling and receptor-expression models; a 2025 paper describes a dedicated tool compound built to dissect how such analogues behave in preclinical models.
What kind of research has been published on Cagrilintide?
The medicinal-chemistry development paper (2021) documents the analogue design and its preclinical characterisation. Reviews of amylin-receptor pharmacology (2015, 2016) provide the receptor framework. A clinical research programme, including combination studies, also exists in the literature; those trials concern regulated investigational medicine development, not laboratory reference material.
The evidence cited here supports pathway and assay design. It is not evidence about any Lazarus Labs product.
What compounds is Cagrilintide studied alongside?
Cagrilintide is studied alongside native amylin and its short-acting analogue pramlintide, and in combination research with the GLP-1 receptor agonist semaglutide. Related incretin research molecules include tirzepatide and retatrutide.
How is Cagrilintide supplied, tested and handled?
Lazarus Labs supplies Cagrilintide 5MG as a lyophilised laboratory reference material with third-party batch documentation and a Certificate of Analysis (COA). Store cold, dry and protected from light in accordance with your laboratory protocol.
References
- Kruse T, Hansen JL, Dahl K, et al. Journal of Medicinal Chemistry. 2021. PMID: 34288673.
- Hay DL, Chen S, Lutz TA, et al. Pharmacological Reviews. 2015. PMID: 26071095.
- Bower RL, Hay DL British Journal of Pharmacology. 2016. PMID: 27061187.
- Gabery S, et al. Life Sciences. 2025. PMID: 40628316.
Primary literature, verified against PubMed. Citations are provided for scientific reference and do not imply a human-use indication.
Important
For research use only. Not for human or veterinary consumption. Cagrilintide is supplied solely as a laboratory reference material. Lazarus Labs makes no therapeutic, medical or performance claims, and nothing on this page is medical advice.